Yesterday, Fujian Cosunter Pharmaceutical Co., Ltd. (hereinafter referred to as “the Company”) received the Clinical Trial Permission signed and issued by the China Food and Drug Administration for Sofosbuvir Tablets.
Adhering to the founding philosophy of “spreading benevolence and caring for the people’s livelihood” and the initial dream of providing scientific solutions for the treatment of Chinese patients with liver diseases, the Company has steadfastly and firmly developed from a startup into a domestic enterprise with the highest market share in the field of anti-hepatitis B treatment within 14 years.
In December 2013, FDA first approved the marketing of Sofosbuvir and its tablets for treating chronic hepatitis C (CHC) infected adults. As the first approved potent oral NS5B inhibitor, Sofosbuvir and Daclatasvir are especially suitable for Chinese patients. With a treatment course of only 12 weeks, which is much shorter than any other treatment regimens, the cure rate of Sofosbuvir and Daclatasvir reaches as high as 100%. Sofosbuvir tablet is a key step for the construction of the product line of Cosunter in the field of hepatic diseases.
Clinical data shows that, the cure rate of an interferon-free oral cocktail regimen consisting of Sofosbuvir and Daclatasvir is 100%, including patients with advanced hepatic diseases or genotype 3 HCV and those that were not cured under the treatment with protease inhibitors. Sofosbuvir and Daclatasvir demonstrate superhigh virological response rate in newly diagnosed and refractory genotype 1 HCV patients. Meanwhile, they are also effective for elderly patients, patients with advanced hepatic diseases, recipient of liver transplantation and patients with HIV/HCV co-infection.
In addition, the fixed combination of Sofosbuvir and Velpatasvir also achieved success in the treatment of chronic hepatitis C. By now, the fixed combination of Sofosbuvir and Velpatasvir has been the only clinically confirmed drug that can simultaneously cure genotype 1, 2, 3, 4, 5 and 6 HCV. The clinical results show that the overall cure rate of its medicinal preparation in treating genotype 1, 2, 3, 4, 5 and 6 HCV is 99%. The SVR12 of various genotypes of hepatitis C is as follows: genotype 1: 98%; genotype 2: 100%; genotype 3: 95%; genotype 4: 100%; genotype 5: 97%; genotype 6: 100%. This drug is the first one that covers all the present genotypes of hepatitis C virus. When such a drug appears on the market in the future, clinicians can directly write out a prescription without detecting the genotypes of hepatitis C.
As one of the highlights in the pharmaceutical industry in recent years, Sofosbuvir shows that Hepatitis C is curable from now on! Cosunter will keep promoting clinical researches, launch the production of Sofosbuvir as soon as possible and boost the development of Sofosbuvir together with Daclatasvir and Velpatasvir which are also globally recognized components of a combination treatment regimen of Hepatitis C.
New platform, new start, new journey and new breakthrough. Cosunter will stay true to its mission. Being grateful and practical, Cosunter will strive to seek solutions for the liver health of Chinese and make the dream of Cosunter a part of Chinese dream for health. Being never satisfied with the achievements obtained, Cosunter will endeavor to make greater progress in the future!